Gregory F. Guzauskas

Author

Also Known As

G F Guzauskas, G. Guzauskas, G.F. Guzauskas, Greg F. Guzauskas, Greg Guzauskas, Gregory F Guzauskas, Gregory F. Guzauskas, Gregory Guzauskas, Guzauskas, Greg

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

University of Washington Geisinger Health System Vanderbilt University Medical Center Pfizer (China)Greenwood Genetic Center

About

Gregory F. Guzauskas is an author at University of Washington specializing in medicine, public health, and clinical genetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	325
2	Public Health	4	4	170
3	Business	1	1	11
4	Engineering	1	1	16
5	Economics	1	1	11

Gregory F. Guzauskas

Publications

990

Citations

H-Index

Page 1

	Year	Citations
Alterations in CDH15 and KIRREL3 in Patients with Mild to Severe Intellectual Disability Kavita Bhalla, Yue Luo, Tim Buchan, The American Journal of Human Genetics Intellectual ImpairmentAutoimmune DiseasePsychiatryNeurological DisorderMedicine	2008	139
Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis Carlos J. Gallego, Brian H. Shirts, Caroline S. Bennette, Journal of Clinical Oncology	2015	124
Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States Gregory F. Guzauskas, Shawn Garbett, Zilu Zhou, JAMA Network Open	2020	87
Meeting the Governance Challenges of Next-Generation Biorepository Research Stephanie M. Fullerton, Nicholas Anderson, Gregory F. Guzauskas, Science Translational Medicine Biomedical EthicResearch EthicsHealth InformationBiobankMedical History	2010	80
Cost-Effectiveness of Recombinant Tissue-Type Plasminogen Activator Within 3 Hours of Acute Ischemic Stroke Denise M. Boudreau, Gregory F. Guzauskas, Er Chen, Stroke	2014	67
Population Genomic Screening for Three Common Hereditary Conditions Gregory F. Guzauskas, Shawn Garbett, Zilu Zhou, Annals of Internal Medicine	2023	65
Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States Josh J. Carlson, Gregory F. Guzauskas, Richard H. Chapman, Journal of Managed Care & Specialty Pharmacy	2017	45
A Model of Cost-effectiveness of Tissue Plasminogen Activator in Patient Subgroups 3 to 4.5 Hours After Onset of Acute Ischemic Stroke Denise M. Boudreau, Gregory F. Guzauskas, Kathleen F. Villa, Annals of Emergency Medicine ThrombosisIschemic StrokeCardiovascular DiseaseMedicineReperfusion Injury	2012	44
Precision Health Economics and Outcomes Research to Support Precision Medicine: Big Data Meets Patient Heterogeneity on the Road to Value Yixi Chen, Gregory F. Guzauskas, Chengming Gu, Journal of Personalized Medicine	2016	40
Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study Gregory F. Guzauskas, Erqi L. Pollom, Volker W. Stieber, Journal of Medical Economics	2019	36

Page 1